Telmisartan, a preparation from the group of angiotensin II receptor blockers widely used for blood pressure correction, significantly increased adiponectin levels in patients with arterial hypertension combined with obesity [156], while perindopril and angiotensin-converting enzyme inhibitor demonstrated the most prominent action on serum leptin reduction among other anti-hypertensive preparations [157]. This evidence concerns the gene LEP and Obesity.